News and Analysis

Versanis Bio scores $70m Series A

Versanis Bio, a developer of medicines that address medical conditions prevalent in older adults, has secured $70 million in Series A financing.

-

Versanis Bio, a developer of medicines that address medical conditions prevalent in older adults, has secured $70 million in Series A financing. Atlas Venture and Medicxi led the round.

Source: Press Release